Granules India’s arm receives USFDA’s approval for Dexmethylphenidate HCl ER Capsules

11 Sep 2020 Evaluate

Granules India’s wholly owned subsidiary--Granules Pharmaceuticals Inc (GPI) has received marketing approval from the U.S. Health Regulator (USFDA) for Dexmethylphenidate HCl extended-release (ER) capsules for the treatment of attention-deficit hyperactivity disorder. Granules’ capsule product is bioequivalent to the reference listed drug (RLD), Focalin XR.

The drug will be manufactured at the Granules manufacturing facility in Chantilly, Virginia. According to IQVIA Health, Dexmethylphenidate HCl ER Capsules had U.S. sales of approximately $556 million for the most recent twelve months ending in July 2020. Granules now have a total of 30 ANDA approvals from the US FDA (28 Final approvals and 2 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

560.70 16.30 (2.99%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×